Given the fact that the mutation rate of GALNTL4 in melanoma tumors is low, it is likely that genetic variant-associated GALNTL4 gene expression may be the mechanism underlying the observed association, which deserves further investigation. This evidence concerns the gene GALNT18 and melanoma.